Massachusetts-based BioSurfaces has developed a process for producing nanofibrous materials out of commonly used FDA-approved polymers. These materials can incorporate drugs or other bioactive agents for localized release. Application of such technology has the potential to help prevent strictures and promote healing of fistulas, which are common manifestations of GI diseases.
Takeda news release, July 26, 2017
Takeda contdracts with US BioSurfaces Inc. on nanomaterials for treatment of GI diseases